We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

203 hedge funds and large institutions have $8.28B invested in Ascendis Pharma A/S in 2024 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 75 increasing their positions, 67 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 23

12% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 67

7% more funds holding

Funds holding: 189 → 203 (+14)

6% more funds holding in top 10

Funds holding in top 10: 16 → 17 (+1)

0.19% less ownership

Funds ownership: 105.35% → 105.16% (-0.19%)

10% less capital invested

Capital invested by funds: $9.19B → $8.28B (-$914M)

52% less call options, than puts

Call options by funds: $21.1M | Put options by funds: $43.9M

Holders
203
Holders Change
+14
Holders Change %
+7.41%
% of All Funds
2.93%
Holding in Top 10
17
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+6.25%
% of All Funds
0.25%
New
38
Increased
75
Reduced
67
Closed
23
Calls
$21.1M
Puts
$43.9M
Net Calls
-$22.8M
Net Calls Change
-$19.3M

Top Buyers

1
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$121M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$83.1M
3
Ameriprise
Ameriprise
Minnesota
+$82.4M
4
Fidelity International
Fidelity International
Bermuda
+$58.7M
5
ACA
Avoro Capital Advisors
New York
+$31.3M

Top Sellers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$345M
2
Artisan Partners
Artisan Partners
Wisconsin
-$187M
3
Brown Advisory
Brown Advisory
Maryland
-$27.9M
4
TD Asset Management
TD Asset Management
Ontario, Canada
-$18.6M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$18.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Pictet Asset Management
51
Pictet Asset Management
Switzerland
$20M -$16.9M -124,443 -46%
Acadian Asset Management
52
Acadian Asset Management
Massachusetts
$19.4M -$14.7M -108,327 -43%
Victory Capital Management
53
Victory Capital Management
Texas
$18.3M -$21.1K -155 -0.1%
BNP Paribas Financial Markets
54
BNP Paribas Financial Markets
France
$17.5M +$7.15M +52,534 +70%
Loomis, Sayles & Company
55
Loomis, Sayles & Company
Massachusetts
$16.6M +$16.5M +121,594 New
SVCM
56
Saturn V Capital Management
Texas
$15.4M +$1.33M +9,796 +9%
Bank of New York Mellon
57
Bank of New York Mellon
New York
$15.1M -$5.48M -40,303 -27%
BC
58
BIT Capital
Germany
$14.3M -$680K -5,000 -5%
AG
59
Artal Group
Luxembourg
$13.8M +$13.8M +101,100 New
SFM
60
Soros Fund Management
New York
$13.6M +$13.1M +96,568 +2,814%
TD Asset Management
61
TD Asset Management
Ontario, Canada
$13.6M -$18.6M -136,924 -58%
SSA
62
Schonfeld Strategic Advisors
New York
$13.4M -$525K -3,859 -4%
GTC
63
Ghost Tree Capital
New York
$11.8M +$11.8M +86,721 New
DCM
64
Driehaus Capital Management
Illinois
$11.1M -$2.57M -18,924 -19%
DCM
65
DAFNA Capital Management
California
$11M -$1.56M -11,500 -12%
Thrivent Financial for Lutherans
66
Thrivent Financial for Lutherans
Minnesota
$10.7M -$4.92M -36,156 -32%
Baillie Gifford & Co
67
Baillie Gifford & Co
United Kingdom
$9.69M -$1.38M -10,135 -12%
JP Morgan Chase
68
JP Morgan Chase
New York
$8.9M +$5.07M +37,256 +133%
Alyeska Investment Group
69
Alyeska Investment Group
Illinois
$8.18M +$8.16M +60,000 New
Geode Capital Management
70
Geode Capital Management
Massachusetts
$7.88M +$229K +1,684 +3%
Qube Research & Technologies (QRT)
71
Qube Research & Technologies (QRT)
United Kingdom
$7.47M +$7.45M +54,748 New
HCA
72
Harbor Capital Advisors
Illinois
$7.12M +$4.11M +30,194 +137%
GF
73
Gray Foundation
New York
$7.05M – – –
ACM
74
ADAR1 Capital Management
Texas
$6.99M +$365K +2,679 +6%
ACM
75
Altium Capital Management
New York
$6.82M +$3.4M +25,000 +100%
1 2
3
4 5

ASND Hedge Fund Activity: Q2 2024 in Review

203 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2024, worth a combined $8.28B — down 9.9% from $9.19B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new ASND positions and 23 closed out — a net gain of 15 holders — while 75 added to existing stakes and 67 trimmed.

The largest buyer was Westfield Capital Management, adding an estimated $121M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $345M.

  • 203 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2024, up from 189 in Q1 2024.
  • Funds reported $8.28B of Ascendis Pharma A/S stock for Q2 2024, down 9.9% quarter-over-quarter.
  • 38 funds opened new Ascendis Pharma A/S positions in Q2 2024 and 23 closed out, a net change of +15 holders.
  • The largest Ascendis Pharma A/S buyer in Q2 2024 was Westfield Capital Management, an estimated $121M added.
  • The largest Ascendis Pharma A/S seller in Q2 2024 was T. Rowe Price Investment Management, an estimated $345M sold.

Based on aggregated 13F filings for Q2 2024.